12:00 AM
 | 
Feb 04, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

OrbeShield regulatory update

FDA granted Fast Track designation for Soligenix's OrbeShield to reduce mortality associated with gastrointestinal acute radiation syndrome (GI ARS). Soligenix plans to conduct a Phase I/II trial of the product in healthy adolescent and young adult volunteers. Last month,...

Read the full 172 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >